Cogent Biosciences, Inc. Common Stock (COGT) is a publicly traded Healthcare sector company. As of July 26, 2026, COGT trades at $39.76 with a market cap of $6.79B and a P/E ratio of -18.41. COGT moved -1.43% today. Year to date, COGT is +11.94%; over the trailing twelve months it is +226.17%. Its 52-week range spans $3.72 to $43.73. Analyst consensus is strong buy with an average price target of $52.43. Rallies surfaces COGT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cogent Biosciences Files Bezuclastinib NDA After 65% APEX ORR: Cogent Biosciences has submitted its third New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, following APEX trial results showing a 65% objective response rate per mIWG criteria and 81% per PPR. The submission complements ongoing PEAK and SUMMIT reviews targeting Q4 2026 approvals.
| Metric | Value |
|---|---|
| Price | $39.76 |
| Market Cap | $6.79B |
| P/E Ratio | -18.41 |
| EPS | $-2.16 |
| Dividend Yield | 0.00% |
| 52-Week High | $43.73 |
| 52-Week Low | $3.72 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-328.94M |
| Gross Margin | 0.00% |
9 analysts cover COGT: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $52.43.